Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BALOISE HOLDING AG - REG. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
BALOISE HOLDING AG - REG
BALOISE HOLDING AG - REG
Net profit above expectations, new share buy-back programme over three years
23 Mar 17
Net attributable profit increased by 4% to CHF535m for FY2016 compared to FY2015. Net premiums earned were down by 3% to CHF6.5bn for FY2016 compared to FY2015. The investment income declined by 3% to CHF1.48bn for 2016. Realised gains on investments rose from CHF386m for FY2015 to CHF667m for FY2016. The investment yield was 2.9% in 2016 compared to 3.0% in 2015. Overall income was flat at CHF8.9bn in 2016 compared to 2015. Insurance claims rose by 6% to CHF5.7bn in the same period. Total expenses were up by 1% to CHF8.2bn in 2016 mainly due to a lower contribution to insurance provisions. Pre-tax profit declined by 5% to CHF646m for FY2016. Tax ratio decreased from 24.7% for FY2015 to 17.3% for FY2016. The net combined ratio of the non-life business declined from 93.3% for 2015 to 92.2% for 2016. Equity capital increased by 6% to CHF5.8bn at the end of 2016 compared to 2015. RoE was 9.7% for FY2016 compared to 9.3% for FY2015. A SST solvency ratio was not released. The dividend proposal rose from CHF5.00 per share for FY2015 to CHF5.20 for FY2016. Baloise also announced a new share buy-back programme over three years of up to three million treasury shares to begin in the first half of 2017.
Weaker H1 profit due to additional reserve needs
30 Aug 16
Pre-tax profit decreased by 17% to CHF289.5m for H1 16 compared to the same period last year. The decrease was mainly due to the addition of CHF54.8m to reserves in the German non-life business, which reduced the net profit for the period by CHF37.9m. Net premiums earned were down by 5% to CHF3.9bn. Investment income was flat at CHF780m for H1 16 compared to H1 15. Realised gains and losses on investments decreased from CHF366m for H1 15 to CHF93m for H1 16. Overall income declined by 10% to CHF4.86bn for H1 16 compared to H1 15. Insurance claims were up by 8% to CHF2.94bn for H1 16. Total expenses were down by 10% to CHF4.6bn in the same period. The net combined ratio of the non-life business was mainly unchanged with 92.5% for H1 16 compared to 92.3% for H1 15. The tax ratio was down from 24.6% for H1 15 to 17.2% for H1 16. Net attributable profit decreased by 10% to CHF224m in H1 16. If it had not added to its reserves, Baloise would have generated a profit of CHF261.5m, up by 5% compared to H1 15. Total equity was unchanged at CHF5.4bn at the end of June 2016 compared to the end of 2015. Baloise reports only on a half-yearly basis.
Solid 2015 figures without disposal gains
22 Mar 16
Net attributable profit decreased by 28% to CHF512m for FY2015 compared to FY2014. 2014 was boosted by disposal gains of around CHF160m due to the sale of the shareholdings in Nationale Suisse and Helvetia and the sale of Basler Austria. Net premiums earned were down by 5% to CHF6.7bn for FY2015 compared to FY2014. The investment result declined by 24% to CHF1.84bn for 2015. The investment yield was down from 4.1% in 2014 to 3.1% in 2015. Overall income decreased by 14% to CHF8.9bn in 2015 compared to 2014. Total expenses were down by 14% to CHF8.2bn in the same period. The net combined ratio of the non-life business declined from 93.6% for 2014 to 93.3% for 2015. Equity capital declined by 6% to CHF5.5bn at the end of 2015 compared to 2014. RoE was 9.3% for FY2015 compared to 13.5% for FY2014. Group solvency was 341% for 2015 compared to 354% for 2014. The dividend proposal was unchanged at CHF5.00 per share for FY2015. Baloise will update its financial targets and focus at its investors day on 26 October 2016.
Very limited Q3 15 information released
17 Nov 15
Total volume of business rose by 1.4% to CHF7.05bn for 9M 15 compared to the same period last year in local currency and on a like-for-like basis. The Group Solvency I ratio was 341% at the end of September 2015 compared to 354% at the end of 2014. No other hard figures were released. Baloise said that it is confident of achieving a combined ratio at the lower end of its own target range of 93-96% in 2015.
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.